AMG133 peptide payload

Metabolic / fat loss

Appetite, glucose, weight, and metabolic regulation

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Incretin / metabolic peptide or small molecule
Primary mechanism: Incretin/amylin/glucagon-axis receptor modulation
Primary market use: Metabolic / fat loss

Pharmacology

Molecular weight (Da): 4600.70
Oral bioavailability: Route-dependent / verify
Half-life: ~12 h–7 days depending analog/acylation
Route tags: SubQ; Injectable; route-dependent
Evidence level: MCE product listing / research chemical signal
Clinical status: Research chemical/reference listing
Value-for-money score: 8 / 10

Reported protocol signal

Vendor product-form signal only, not a protocol: AMG133 peptide payload

For orientation only. See disclaimer — always consult a licensed clinician before use.

Stackability

Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.

Notes

AMG133 peptide payload TFA is a GLP-1 analog agonist peptide. AMG133 peptide payload TFA potently activates GLP-1R and exhibits weight loss and metabolic improvement activities. AMG133 peptide payload TFA can be used for the synthesis of AMG 133 ( HY-164535 ).

Sources

https://www.medchemexpress.com/amg133-peptide-payload.html